Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253017 | 0.83 | LOX (0.41) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL1404067 | 0.83 | LOX (0.41) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL21245368 | 0.77 | ALOX5 (0.31) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL27698215 | 0.75 | CASR (0.37) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL30015590 | 0.75 | CA2 (0.40) | — | |
| SCHEMBL247456 | 0.75 | CA2 (0.40) | — | |
| SCHEMBL12753748 | 0.75 | ALDH1A1 (0.44) | GRM5HTR7HTR1ADRD2HTR2A | |
| SCHEMBL3384804 | 0.74 | HTR7 (0.38) | HTR7HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL28231028 | 0.73 | CASR (0.36) | GRM5 | |
| SCHEMBL21245333 | 0.72 | WEE1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| WO-2018011569-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248795-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | WEE1, WEE2, PPME1 | CDK1 16/4885CDK2 59/4885KDR 2032/4885 |
| US-10766902-B2 | Wee-1 inhibiting pyrazolopyrimidinone compounds | WEE1, WEE2, PPME1 | CDK1 17/4885CDK2 64/4885KDR 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.